Kadriye Baskurt, Medical Oncologist at Etlik City Hospital, shared a post on X:
“ESMO25 Highlight!
The Phase III FORTITUDE-101 trial demonstrates improved short-term survival with bemarituzumab + chemotherapy in FGFR2b-overexpressing gastric and GEJ cancer patients.
A new step forward for precision oncology in upper GI malignancies.”
You can also read: FORTITUDE-101 Trial at ESMO 2025 Presidential: BEMA Plus Chemotherapy in FGFR2b-Positive Gastric Cancer
